Atossa Reports Progress & Results Timeline For Male Breast Enlargement Trial

Seattle based Atossa Genetics Inc. (ATOS) (“Atossa”) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.  Atossa is developing topical Endoxifen for a condition in men called gynecomastia, which is male breast enlargement.

Mayo Clinic Research

According to the Mayo Clinic, 25% of men in the U.S. between the ages of 50-69, or approximately 10 million men, suffer from gynecomastia. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone is low compared to estrogen.  For example, in prostate cancer treatment, testosterone is suppressed with androgen deprivation therapy resulting in higher estrogen levels that usually triggers gynecomastia. One recent study indicates that up to 90% of men taking androgen deprivation therapy suffer from gynecomastia and breast pain (Handoo Rhee, et al., October 18, 2014, BJU International). There is no FDA-approved pharmaceutical to treat gynecomastia. Current therapeutic approaches in these patients include the daily use of oral estrogen-suppressing medications and prophylactic breast bud irradiation which is often repeated.

 

 

 

 

 

Progress Announced!

Today, Atossa announced progress in its Phase 1 study of its proprietary topical Endoxifen in men as it has reported that it has completed dosing and clinical visits. The objectives of the placebo-controlled, repeat dose study of 24 healthy male volunteers are to assess the pharmacokinetics of a proprietary topical Endoxifen dosage form over 28 days, as well as to assess safety and tolerability.

Steve Quay, Ph.D., M.D., President and CEO of Atossa stated, “We are now proceeding to the final stages of this study, which are to complete analysis of blood samples and then collect and analyze the data. We expect to report preliminary results from the study in the next quarter.”

Atossa Reaches Further

In addition to gynecomastia, Atossa is also developing its proprietary topical Endoxifen to reduce Mammographic Breast Density (MBD), which has been shown in studies conducted by others to be an independent risk factor for developing breast cancer. To date, 34 U.S. states have enacted laws requiring that findings of MBD be communicated to the patient. And according to the National Cancer Institute, approximately 10 million women in the U.S. have high breast density (BI-RADS level C or D with “D” being the highest). Although oral tamoxifen has been shown to reduce MBD, the benefit-risk ratio is generally not acceptable to most patients. For example, it is estimated that only ~ 2% of women at high-risk of developing breast cancer, including those with MBD, take oral tamoxifen to prevent breast cancer because of the risks of, or actual side-effects of, oral tamoxifen. There is no FDA-approved treatment for MBD.

Atossa is planning a Phase 2 study of its topical Endoxifen in women with MBD. The study will be conducted at Stockholm South General Hospital in Sweden and will be led by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet.

The primary endpoint of this study is to determine if topical Endoxifen administration results in an individual change in MBD, which will be measured after three and six months. Secondary endpoints are safety and tolerability. The objective of the study is to determine the effect size on MBD between the placebo and active groups, which will permit sample size calculations in a future Phase III study. Enrollment is anticipated to be completed by the end of 2018.

Shares Surge

Shares of Atossa (ATOS) surged to as high as $3/share and traded ~2.62 million shares today and closed at $2.63/share up +5.2%.

Analyst Update

Maxim Group’s Biotechnology Analyst Jason McCarthy issued an update report and maintained his “Buy rating” and his $10/price target.

Learn More

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has completed dosing and clinical visits in its Phase 1 study of its proprietary..

finance.yahoo.com

Read Full Article



Merck’s KEYTRUDA Gains Additional Approval From FDA

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the leading edge of research.

Merck recently announced the U.S. Food and Drug Administration’s approval of the company’s anti-PD-1 therapy KEYTRUDA®. The therapy is used to treat patients who have recurrent or metastatic cervical cancer with disease advancement on or after chemotherapy and with tumors that express PD-L1. The indication for the use of this therapy is approved under the FDA’s accelerated approval regulations that are based on both tumor response rate and the durability of response.

KEYTRUDA is now the first anti-PD-1 therapy approved for the treatment of advanced cervical cancer, providing an important new second-line option for certain patients with this disease. This approval also marks the first indication for KEYTRUDA in a gynecologic cancer and reflects our ongoing commitment to bring forward innovative treatment options across a broad range of cancers, including cancers that disproportionately affect women.” -Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories

With KEYTRUDA, some immune-mediated adverse reactions did occur. Those included were as follows: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, severe skin reactions, and solid organ transplant rejection.

To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page. 

Free stock photo of landscape, nature, sky, clouds

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

View of City Street

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)

Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose..

finance.yahoo.com

Read Full Article



Breast Cancer Innovator Atossa Genetics Adds Former Pfizer & Janssen Pharmacuetica NV Execs To SAB

Seattle based Atossa Genetics Inc. (ATOS) (“Atossa”) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.  This week, Atossa appointed two additional pharmaceutical executives to its strategic advisory board (“SAB”) as they named former Pfizer executive, Dr. Makarand (Mak) Jawadekar and Dr. Ajit Shetty, Chairman of the Belgium-based Flemish Institute of Biotechnology and former Janssen Pharmaceutica NV executive. The board is positioned to play a key role in a number of important strategic initiatives in accelerating the clinical development of Atossa’s programs.

Steven Quay, Ph.D., MD, President and CEO of Atossa stated, “We are very excited to have both Dr. Jawadeker and Dr. Shetty join our advisory board.  Each of these lauded industry veterans brings unique sets of talents and experiences to our company. Their insights and direction will be invaluable in developing our strategic initiatives to advance our therapeutics.

Dr. Mak Jawadekar’s professional career at Pfizer, Inc. spanned 28 consecutive years, most recently as a Director, Portfolio Management. During his career at Pfizer, he was responsible for the Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies and has extensive experience in creating and cultivating external partnerships and alliances in this area. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota. Mak was honored with an honorary D.Sc. degree by DYP Mumbai University, recommended by the President of India in Feb 2011. His years of experience with Pfizer Global R&D includes Solids R&D, Drug Product Formulation/ Dosage Form/Drug Delivery development, Clinical Trials Supply Manufacturing, and Scale-up and Technology Transfer & Research Pharmacy functions. At Pfizer he was also a bench scientist, working on many challenging commercial formulations which became multibillion-dollar products.

Dr. Shetty spent his 40-plus year career at Janssen Pharmaceutica NV in Belgium (a Johnson & Johnson company) in which he drove the expansion of the Janssen Group of Companies through geographical expansion, new product introduction, and significant market share growth. In his prior capacity as President of Janssen Pharmaceutica USA, Dr. Shetty launched Janssen USA into the largest pharmaceutical market. Currently, Dr. Shetty is Chairman of the Belgium-based Flemish Institute of Biotechnology, one of the world’s top-ten research institutions. In 2008, he was awarded the title of Baron by the King of Belgium and in 2004 was elected Manager of the Year by Trends/Flemish Management Association. He is a member of the Board of Directors at Agile Therapeutics, Actinium Pharmaceuticals, and is a member of the Board of Trustees of Carnegie Mellon University.

 

 

 

 

 

 

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced the appointment of two additional pharmaceutical executives to its strategic advisory..

finance.yahoo.com

Read Full Article



Johnson & Johnson Receives Binding $2.8B Aggregate Value Offer From Fortive Corporation

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services.

Johnson & Johnson announced the obtainment of a binding offer from Fortive Corporation for the acquirement of its Advanced Sterilization Products. ASP is a division of the New Jersey corporation Ethicon, Inc. The offer was for an aggregate value of about $2.8B. ASP, a worldwide leader in inventive infection prevention solutions has a net revenue in 2017 of $775 million.

Advanced Sterilization Products helps healthcare facilities prevent hospital-acquired infections, the leading cause of morbidity and mortality. ASP uses capital, consumables, and software for used in Low-Temperature Terminal Sterilization and High-Level Disinfection of reusable surgical instruments.

There is a 120 day period for the acceptance of the offer. If accepted, the purchase would be predicted to close in early 2019 at the latest.

To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Happy Friends With Arms Outstretched in City during Winter

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive!
Join us at Vista Partners! It’s FREE to receive email updates.

Johnson & Johnson Announces Binding Offer from Fortive Corporation to Acquire Advanced Sterilization Products (ASP)

NEW BRUNSWICK, N.J., June 6, 2018 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Fortive Corporation (NYSE: FTV) to acquire its Advanced Sterilization Products (ASP) business, a division of Ethicon, Inc.*, for an aggregate value of approximately $2.8 billion, consisting of $2.7 bi…..

www.investor.jnj.com

Read Full Article



Atossa Genetics Closes Net Proceeds of $12.1M From Rights Offering- Sees CE0, CFO Insiders Participate

Seattle based Atossa Genetics Inc. (NasdaqCM: ATOS) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.

According to Atossa Genetic’s latest 8k filing, Atossa, on May 30, 2018,  completed its previously announced rights offering pursuant to its effective registration statement on Form S-1, as amended (Registration Statement No. 333-223949), previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”), and a prospectus filed with the SEC (the “Rights Offering”).

Pursuant to the Rights Offering, the Company sold an aggregate of 13,324 units consisting of an aggregate of 13,324 shares of Series B Preferred Stock and 3,784,016 warrants, with each warrant exercisable for one share of Common Stock at an exercise price of $4.05 per share, resulting in net proceeds to the Company of approximately $12.1 million, after deducting expenses relating to the Rights Offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. In connection with the Rights Offering, the Company entered into a Warrant Agency Agreement with VStock Transfer, LLC. A copy of the agreement is filed as Exhibit 4.1 to this report and is incorporated by reference herein.

Also,  according to Form 4’s filed 5-31-18 with the SEC, Atossa realized insider buying as their CEO, Steven Quay &  their CFO Kyle Guse & an insider, Chen Shu-Chih, invested in this recent rights offering. Note that CFO Kyle Guse purchased stock in the Fall 2017.

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Breast Cancer Innovator Atossa Genetics Accepts Subscriptions For ~$13.4MM Gross Proceeds Rights Offering

Seattle based Atossa Genetics Inc. (NasdaqCM: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast condition,  announced today that the Company’s previously announced rights offering (“the Rights Offering”) expired on Thursday, May 24, 2018 and these rights are no longer exercisable. The Company reports that it has accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in ~$13.4MM in gross proceeds. The results of the Rights Offering and Atossa’s estimates regarding the aggregate gross proceeds of the Rights Offering to be received by Atossa are subject to finalization and verification by Atossa and its subscription agent. Atossa engaged Maxim Group LLC as dealer-manager in the offering. Questions about the rights offering may be directed to Maxim Group LLC at 405 Lexington Avenue, New York, NY 10174, Attention Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.

Atossa expects the closing of the Rights Offering will occur on or about May 30, 2018 subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book­-entry form or through the facilities of DTC, as applicable, shares of its Series B Convertible Preferred Stock and warrants to holders of rights who have validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to such holders. Each right entitled the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series B Convertible Preferred Stock with a face value of $1,000 (and immediately convertible into 284 shares of common stock at a conversion price of $3.52 per share) and 284 warrants with an exercise price of $4.05. The warrants will be exercisable for 4 years after the date of issuance.

Atossa Genetics (ATOS) also recently received a second positive interim safety review on its Phase 1 study of topical Endoxifen in men, which is being developed to address gynecomastia (or male breast enlargement). The objectives of this double-blinded, placebo-controlled, repeat dose study of 24 healthy male subjects are to assess the pharmacokinetics of proprietary formulations of topical endoxifen dosage forms over 28 days, as well as to assess safety and tolerability. The study is being conducted on behalf of Atossa by CPR Pharma Services Pty Ltd., Thebarton, SA, Australia. The Independent Safety Committee reviewed the blinded data generated from the second group in the study (eight subjects) and concluded that the study may advance to the final dosing level.

Gynecomastia is male breast enlargement and accompanying pain. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone is low compared to estrogen. In prostate cancer treatment, testosterone is suppressed resulting is higher estrogen levels that usually triggers gynecomastia. Prophylactic breast bud irradiation is commonly used in prostate cancer patients, but must often be repeated. One recent study indicates that up to 90% of men taking androgen deprivation therapy suffer from gynecomastia and breast pain (Handoo Rhee, et al., October 18, 2014, BJU International).  According to the Mayo Clinic, although it can affect men at almost any age, it is most prevalent in men ages 50-69, affecting at least 1 in 4 men in this age group. Gynecomastia is caused by, among other things, any number of commonly prescribed medications, such as androgen deprivation therapy to treat prostate enlargement and prostate cancer; anti-anxiety medications; cancer treatments (chemotherapy), and some heart medications. Gynecomastia is not only painful and embarrassing, it can also cause men to stop taking these important medications.

Shares of ATOS are currently trading at $3.30, up +0.10/share  or +3.12% today.

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

Atossa Announces $13.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering

Atossa Genetics Inc. (“Atossa” or “the Company”) announced today that the Company’s previously announced rights offering (“the Rights Offering”) expired on Thursday, May 24, 2018, and these rights are no longer exercisable. The Company accepted all valid subscriptions that were presented…

finance.yahoo.com

Read Full Article



New Asia Pacific Headquarters for Johnson & Johnson in Singapore

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services.

Johnson & Johnson recently opened a new Asia Pacific Headquarters in Singapore’s Science Park. The new headquarters is characterized by a cutting-edge design lab, a leadership lab, as well as the company’s first international Johnson & Johnson Human Performance Institute.

With the Asia Pacific region being home to half the world’s population and nearly 80% of that region not having access to healthcare, Johnson & Johnson believes it has a responsibility as the world’s largest healthcare company to take on this challenge to bring accessible and affordable healthcare to this region.

The three new facilities located in the Singapore Science Park will allow Johnson & Johnson to find an innovative way to work with the regions government bodies, healthcare agencies, and academic institutions to bring training, classes, and products to the Asia Pacific region.

To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Marina Bay Sands, Singapore

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive!
Join us at Vista Partners! It’s FREE to receive email updates.

Johnson & Johnson Opens a New Asia Pacific Headquarters

Located in Singapore’s Science Park, Johnson & Johnson?s new regional headquarters will feature a cutting-edge Design Lab, Leadership Lab and the company’s first international Johnson & Johnson Human Performance Institute. Learn more…

www.jnj.com

Read Full Article



Breast Cancer Innovator Atossa Genetics Receives Second Positive Interim Safety Review from Independent Safety Committee in Study of Men With Male Breast Enlargement

Seattle based Atossa Genetics Inc. (ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, has received a second positive interim safety review on its Phase 1 study of topical Endoxifen in men, which is being developed to address gynecomastia (or male breast enlargement). The objectives of this double-blinded, placebo-controlled, repeat dose study of 24 healthy male subjects is to assess the pharmacokinetics of proprietary formulations of topical endoxifen dosage forms over 28 days, as well as to assess safety and tolerability. The study is being conducted on behalf of Atossa by CPR Pharma Services Pty Ltd., Thebarton, SA, Australia. The Independent Safety Committee reviewed the blinded data generated from the second group in the study (eight subjects) and concluded that the study may advance to the final dosing level.

Gynecomastia is male breast enlargement and accompanying pain. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone is low compared to estrogen. In prostate cancer treatment, testosterone is suppressed resulting is higher estrogen levels that usually triggers gynecomastia. Prophylactic breast bud irradiation is commonly used in prostate cancer patients, but must often be repeated. One recent study indicates that up to 90% of men taking androgen deprivation therapy suffer from gynecomastia and breast pain (Handoo Rhee, et al., October 18, 2014, BJU International).  According to the Mayo Clinic, although it can affect men at almost any age, it is most prevalent in men ages 50-69, affecting at least 1 in 4 men in this age group. Gynecomastia is caused by, among other things, any number of commonly prescribed medications, such as androgen deprivation therapy to treat prostate enlargement and prostate cancer; anti-anxiety medications; cancer treatments (chemotherapy), and some heart medications. Gynecomastia is not only painful and embarrassing, it can also cause men to stop taking these important medications.

Atossa will host a corporate conference call to discuss the Company’s business on Wednesday, May 16, 2018, at 4:30 EDT. The call is being provided so that stockholders and potential investors can hear directly from senior management about the Company’s business with a focus on recent developments. Due to expected high call attendance, participants are asked to pre-register for the call through the following link: http://dpregister.com/10120189. Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without internet access or who are unable to pre-register may dial in by calling: 1-844-824-3830 (domestic), 1-412-317-5140 (international) and Canada Toll-Free: 1-855-669-9657. Callers should ask to be joined into the Atossa Genetics call.

The conference call will also be available through a live webcast through the Company’s IR events page at http://ir.atossagenetics.com/ir-calendar or through the following link: https://services.choruscall.com/links/atos180507.html.

Dr. Steven Quay, Ph.D., MD, President and CEO of Atossa stated, “We can now advance to the next level of the study which is to escalate the dosage in the third and final cohort of subjects as we continue to monitor safety and tolerability in the first and second cohorts of the study. We plan to complete enrollment this quarter and announce results from the study next quarter.”

There are no FDA-approved therapeutics for gynecomastia. Breast-bud irradiation, use of compression garments and plastic surgery are the most common approaches used to treat gynecomastia.

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Atossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received a second positive interim safety review on its Phase 1 study of..

finance.yahoo.com

Read Full Article



May 13-19 Is National Women’s Health Week

The week of May 13-19, 2018 is National Women’s Health Week (“NWHW”). This is a week that serves as a reminder to women and encourages them to make their health a priority. The U.S. Department of Health and Human Services’ Office on Women’s Health is the leader of NWHW and seeks to use this week as a tool to remind women to build positive health habits for life.

The Office on Women’s Health lists several steps that can be taken for better health which includes:

  • Scheduling a well-woman visit and preventive screenings
  • Getting Active
  • Eating Health
  • Paying attention to mental health
  • Avoiding unhealthy behaviors

There are multiple ways to participate in National Women’s Health Week :

  • Learn about the steps that can be taken for good health, no matter age
  • Take the National Women’s Health Week Quiz to test your knowledge on healthy living
  • Use the #NWHW on social media, to show how you’re making your health a priority
  • Join the National Women’s Health Week Thunderclap
  • Organize your own community events and activities

For more resources and information on National Women’s Health Week, visit https://www.womenshealth.gov/nwhw/about

Woman With White Sunvisor Running

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

About National Women’s Health Week

National Women’s Health Week, led by the HHS Office on Women’s Health, aims to empower women to make their health a priority…

www.womenshealth.gov

Read Full Article



Seattle’s Atossa Genetics Publishes Q1 2018 Financial Results & Company Update – Schedules Call For May 16 4:30pm EDT

Seattle based Atossa Genetics Inc. (ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, publishes its Q1 ended March 31, 2018, financial results and provided an update on recent company developments.

Atossa’s highlighted the following developments:

  • May 2018 – Formed strategic advisory board to accelerate growth with prominent former pharmaceutical executives from Pfizer and Boehringer Ingelheim.
  • April 2018 – Received approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2 Study of proprietary topical Endoxifen for the treatment of women with mammographic breast density.
  • April 2018 – Received a positive interim safety review on the Phase 1 study of topical Endoxifen in men, which is being developed to address gynecomastia (or male breast enlargement).
  • April 2018 – Announced a reverse split of common stock at a ratio of 1-for-12 that was effective on April 20, 2018, and which led to regaining compliance with Nasdaq.
  • March 2018 – Announced that Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Stockholm, Sweden had been appointed as Scientific Advisor.
  • March 2018 – Expanded the breast health program by launching a men’s’ breast health initiative with enrollment opening in a Phase 1 study of the proprietary topical Endoxifen in men.
  • February 2018 – Announced important additional findings from the Phase 1 study of Atossa’s proprietary oral Endoxifen.
  • We generated no revenue or cost of revenue for the three months ended March 2018.
  • Currently, we are in the research and development phase and do not market any products and services.
  • The Company recorded a net loss of $1.9 million for the three months ended March 31, 2018.
  • Total operating expenses were approximately $1.9 million for the three months ended March 31, 2018, consisting of general and administrative (G&A) expenses of approximately $1.4 million, and research and development (R&D) expenses of approximately $0.5 million.
  • Total operating expenses were approximately $1.7 million for the three months ended March 31, 2017, consisting of G&A expense of approximately $1.2 million and R&D expenses of $0.5 million.

Steve Quay, President and CEO, commented, “During the first part of 2018, we have continued to make significant advances driving toward the next phase of our clinical plans – including a new program in men’s breast health and receiving regulatory approval to commence our Phase 2 breast density study in Sweden. We are especially excited about engaging additional experts that will advise us on important initiatives including seeking partners in the pharmaceutical industry to accelerate the clinical development of our Endoxifen programs. This quarter, we plan to complete our Phase 1 study of topical Endoxifen in men, commence enrollment in our Phase 2 study of topical Endoxifen in women with mammographic breast density, and open our Phase 2 study of oral Endoxifen in women who are “refractory” to tamoxifen.”

Atossa will host a corporate conference call to discuss the Company’s business on Wednesday, May 16, 2018, at 4:30 EDT. The call is being provided so that stockholders and potential investors can hear directly from senior management about the Company’s business with a focus on recent developments. Due to expected high call attendance, participants are asked to pre-register for the call through the following link: http://dpregister.com/10120189. Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without internet access or who are unable to pre-register may dial in by calling: 1-844-824-3830 (domestic), 1-412-317-5140 (international) and Canada Toll-Free: 1-855-669-9657. Callers should ask to be joined into the Atossa Genetics call.

The conference call will also be available through a live webcast through the Company’s IR events page at http://ir.atossagenetics.com/ir-calendar or through the following link: https://services.choruscall.com/links/atos180507.html.

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.
Atossa Genetics Announces First Quarter 2018 Financial Results And Provides Company Update

SEATTLE, May 14, 2018– Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced …..

finance.yahoo.com

Read Full Article